- Trials with a EudraCT protocol (89)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
89 result(s) found for: cancer.
Displaying page 1 of 5.
EudraCT Number: 2008-005074-12 | Sponsor Protocol Number: 20070411 | Start Date*: 2009-03-04 | |||||||||||||||||||||
Sponsor Name:Amgen Inc | |||||||||||||||||||||||
Full Title: A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination with AMG 479 in Subjects with Advanced, Refractory Solid Tumors. -------------------------------------------------------- Es... | |||||||||||||||||||||||
Medical condition: Part 1: Advanced, treatment-refractory solid tumors Part 2: Advanced non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, ovarian cancer, or sarcoma. --------------------... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004281-10 | Sponsor Protocol Number: PT/11/2017 | Start Date*: 2018-01-10 | |||||||||||||||||||||
Sponsor Name:Department of Pediatric oncology, Aarhus University hospital | |||||||||||||||||||||||
Full Title: Pharmacokinetics and pharmacodynamics of Piperacillin-Tazobactam (PT) in pediatric oncology patients with fever and neutropenia | |||||||||||||||||||||||
Medical condition: Pediatric oncology patients with fever | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004062-29 | Sponsor Protocol Number: RHMCAN1142 | Start Date*: 2016-02-01 |
Sponsor Name:University Hospital Southampton NHS Trust | ||
Full Title: SGI-110 to potentiate platinum response: A phase Ib/randomised IIa open label clinical trial combining SGI-110 with cisplatin and gemcitabine chemotherapy | ||
Medical condition: Solid Malignancies including Bladder Cancer | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-002029-31 | Sponsor Protocol Number: CRUKD/12/002 | Start Date*: 2013-11-19 | |||||||||||
Sponsor Name:Cancer Research UK | |||||||||||||
Full Title: A Cancer Research UK Phase I/II study to compare [124I]mIBG PET/CT to [123I]mIBG imaging in patients with metastatic neuroblastoma | |||||||||||||
Medical condition: newly diagnosed, relapsed or refractory metastatic neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005542-23 | Sponsor Protocol Number: CR0708-11 | Start Date*: 2009-07-27 | |||||||||||
Sponsor Name:Cancer Research UK | |||||||||||||
Full Title: A CCLG/Cancer Research UK Phase I Trial of AT9283 (a selective inhibitor of Aurora kinases) given for 72 hours every 21 days via intravenous infusion in children and adolescents with relapsed and r... | |||||||||||||
Medical condition: Relapsed and refractory solid tumours in children and adolescents | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003025-18 | Sponsor Protocol Number: VAPER | Start Date*: 2015-05-08 |
Sponsor Name:King's College London [...] | ||
Full Title: In Vivo Generation of Optimal Tumour Antigen-specific Anticancer Immune Responses, by Vaccination with Human Telomerase Reverse Transcriptase (hTERT) Peptides, in Combination with Specific Adjuvant... | ||
Medical condition: Advanced malignancies | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004742-18 | Sponsor Protocol Number: XM22-07 | Start Date*: 2012-04-04 |
Sponsor Name:Merckle GmbH, a member of the ratiopharm group, a subsidiary of Teva Pharmaceutical Industries Ltd. Germany | ||
Full Title: Multicenter, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, Tolerability, and Immunogenicity of a Single, Subcutaneous Dose of 100μg/kg XM22 in 21 Children wit... | ||
Medical condition: Children with Ewing Family of Tumors or Rhabdomyosarcoma receiving cytotoxic Chemotherapy for malignancy inducing neutropenia | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: HU (Completed) CZ (Completed) BG (Completed) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-005978-51 | Sponsor Protocol Number: TED6421 | Start Date*: 2008-08-22 |
Sponsor Name:sanofi-aventis recherche & développement | ||
Full Title: Uncontrolled, multicenter, dose finding, safety and pharmacokinetic study of AVE1642, an anti-Insulin-like Growth Factor-1 Receptor (IGF-1R/ CD221) monoclonal antibody, administered as single agent... | ||
Medical condition: Advanced solid tumors | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-002777-32 | Sponsor Protocol Number: 110659 | Start Date*: 2007-10-23 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A phase I/II, partially blind, randomized, multicentre, age-stratified, dose-range study in healthy females aged 9 - 25 years to assess the safety and immunogenicity of GlaxoSmithKline Biologicals’... | |||||||||||||
Medical condition: For active immunization of females for the prevention of cervical cancer by protecting against persistent infections, cytological abnormalities including atypical squamous cells of undetermined sig... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001224-36 | Sponsor Protocol Number: A4021010 | Start Date*: 2005-06-10 |
Sponsor Name:Pfizer Inc. - Research & Development | ||
Full Title: Phase 1, Open Label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CP-751,871 in Patients with Advanced Solid Tumours | ||
Medical condition: Advanced Solid Tumours | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-001577-33 | Sponsor Protocol Number: D24-DIPG | Start Date*: 2016-11-03 |
Sponsor Name:Clínica Universidad de Navarra | ||
Full Title: Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma newly diagnosed in pediatric patients. | ||
Medical condition: Diffuse Intrinsic Pontine Glioma newly diagnosed in pediatric patients. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003872-37 | Sponsor Protocol Number: S63142 | Start Date*: Information not available in EudraCT |
Sponsor Name:University Hospitals Leuven | ||
Full Title: 18F-MFBG PET imaging of the norepinephrine transporter in neural crest and neuroendocrine tumors: a phase I PET/CT study | ||
Medical condition: Neural crest tumors and neuroendocrine tumors | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-002675-19 | Sponsor Protocol Number: TMZ-CSF-001 | Start Date*: 2015-10-06 |
Sponsor Name:Medical University of Vienna, Department of Pediatrics | ||
Full Title: Pharmacokinetics of temozolomide in cerebrospinal fluid in children with malignant brain tumors | ||
Medical condition: Recurrent malignant childhood central nervous system tumors | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-004680-39 | Sponsor Protocol Number: AUTO3-PA1 | Start Date*: 2017-06-21 | ||||||||||||||||
Sponsor Name:Autolus Limited | ||||||||||||||||||
Full Title: A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 in Paediatric and Adult Patients with R... | ||||||||||||||||||
Medical condition: Acute lymphoblastic leukaemia (ALL) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-005943-24 | Sponsor Protocol Number: 580299/011 | Start Date*: 2006-03-29 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase I/II, observer-blind, randomized, controlled study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according t... | ||
Medical condition: In female subjects from 10 years of age onwards for the prevention of cervical cancer by protecting against incident and persistent infections, cytological abnormalities including ASC-US, cervical ... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | |
Trial protocol: FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003632-71 | Sponsor Protocol Number: DEND/TIA | Start Date*: 2014-07-14 |
Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra | ||
Full Title: Dendritic cell-based immunotherapy for advanced solid tumours of children and young adults | ||
Medical condition: Children and young adults with advanced solid tumours: relapsed or metastatic sarcomas or central nervous system tumours. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-001422-23 | Sponsor Protocol Number: PCD4989g | Start Date*: 2012-06-01 | |||||||||||
Sponsor Name:Genentech Inc | |||||||||||||
Full Title: A PHASE I, OPEN LABEL, DOSE ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB (MPDL3280A) ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT TO PATIENTS WITH LOCALLY ADVANCED OR METASTA... | |||||||||||||
Medical condition: Advanced or Metastatic Solid Tumors or Hematologic Malignancies | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000015-24 | Sponsor Protocol Number: 07MI05 | Start Date*: 2015-04-10 |
Sponsor Name:Great Ormond Street Hospital | ||
Full Title: 90-Yttrium-labelled anti-CD66 monoclonal antibody as part of a reduced intensity conditioning regimen prior to allogeneic haematopoietic stem cell transplantation: an open label, dose escalating ph... | ||
Medical condition: High risk relapsed or refractory leukaemia in childhood | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000296-24 | Sponsor Protocol Number: CL1-68587-002 | Start Date*: 2017-10-20 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S) | |||||||||||||
Full Title: Phase I, open label, dose-escalation study to evaluate the safety, expansion and persistence of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen recepto... | |||||||||||||
Medical condition: Patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL). | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006197-88 | Sponsor Protocol Number: FANCOSTEM-1 | Start Date*: 2012-03-22 | |||||||||||
Sponsor Name:Cristina Díaz de Heredia Rubio | |||||||||||||
Full Title: Clinical Phase II Trial to evaluate efficacy and safety of CD34+ cells mobilization and collection after treatment with plerixafor and filgrastim in patients with Fanconi anemia for subsequent tra... | |||||||||||||
Medical condition: Fanconi anemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
